Compare VIR & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | TROX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2019 | 2012 |
| Metric | VIR | TROX |
|---|---|---|
| Price | $11.31 | $5.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $19.43 | $6.36 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.07% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $68,556,000.00 | ★ $2,898,000,000.00 |
| Revenue This Year | $270.22 | $6.94 |
| Revenue Next Year | N/A | $5.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.75 | $2.86 |
| 52 Week High | $11.66 | $10.59 |
| Indicator | VIR | TROX |
|---|---|---|
| Relative Strength Index (RSI) | 73.93 | 40.16 |
| Support Level | $8.43 | $4.08 |
| Resistance Level | $11.66 | $6.94 |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | 0.25 | -0.03 |
| Stochastic Oscillator | 93.86 | 14.94 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.